Human Albumin Kedrion (Human Albumin Solution)

Human Albumin Kedrion is indicated for clinical situations where rapid plasma volume expansion is required. It is commonly employed in the management of hypovolemia, shock, extensive burns, and hypoalbuminemia.

• Treatment of hypovolemia due to trauma, surgery, or dehydration.
• Management of circulatory shock when fluid resuscitation is needed.
• Support of patients with severe burns to replace lost plasma proteins.
• Correction of hypoalbuminemia associated with liver disease or nephrotic syndrome.
• Volume expansion during major surgical procedures or cardiac bypass.

• Human Albumin Kedrion works by increasing the oncotic pressure of plasma. The infused albumin molecules remain within the intravascular compartment, drawing water from the interstitial space into the bloodstream. This osmotic shift expands circulating blood volume, improves tissue perfusion, and helps maintain hemodynamic stability. The effect is mediated through albumin’s natural binding capacity for water and various endogenous substances, without directly interacting with cellular receptors.

Adverse reactions to Human Albumin Kedrion are generally infrequent but can range from mild to severe.

Common

• Fever, chills, or rigors occurring during or shortly after the infusion.
• Headache, light‑headedness, or transient dizziness that resolves without intervention.
• Nausea, vomiting, or mild abdominal discomfort.
• Localized urticaria, pruritus, or erythema at the infusion site.

Serious

• Anaphylaxis or severe hypersensitivity reaction characterized by bronchospasm, hypotension, or angio‑edema.
• Acute renal failure or hemolysis manifested by sudden rise in serum creatinine or hemoglobinuria.
• Volume overload resulting in pulmonary edema, hypertension, or congestive heart failure.

Before using Human Albumin Kedrion, clinicians should assess patient history and monitor specific clinical parameters to reduce risk.

• Verify absence of known hypersensitivity to albumin or any plasma‑derived products.
• Assess fluid status and avoid administration in patients with uncontrolled heart failure or severe pulmonary edema.
• Monitor blood pressure, central venous pressure, and urine output during and after infusion.
• Use caution in patients with renal impairment, liver disease, or coagulopathy.
• Adjust dose or infusion rate in neonates, infants, and elderly patients.
• Ensure appropriate viral inactivation and screening of the plasma source.

Human Albumin Kedrion may interact with other therapies that affect fluid balance, coagulation, or immune response.

Avoid

• Avoid concurrent administration with high‑dose diuretics that may precipitate rapid intravascular volume depletion.
• Do not mix with incompatible solutions such as those containing calcium chloride or potassium phosphate.

Use with caution

• Use with caution when combined with other plasma expanders (e.g., hydroxyethyl starch) to prevent excessive volume expansion.
• Caution is advised when administering together with anticoagulants, as albumin can alter plasma protein binding.
• Monitor closely when given alongside immunosuppressive agents, because albumin may affect drug distribution.